Warren Buffett Detailed Fundamental Analysis

Validea's guru fundamental report indicates Accenture PLC (ACN) scores 77% using its Warren Buffett-inspired Patient Investor model, placing it just below the threshold for 'some interest' for this strategy. ACN, a large-cap growth stock in Computer Services, demonstrates strong alignment with Buffett's criteria for predictable profitability, low debt, and robust returns, passing most fundamental tests including earnings predictability and free cash flow. However, the stock notably failed the 'Initial Rate of Return' criterion, contributing to its 77% score and suggesting it may not currently meet the strict valuation requirements for a strong buy signal from this long-term value strategy.

Analysis

Accenture PLC (ACN) scores a 77% rating based on Validea's Patient Investor model, which emulates the investment strategy of Warren Buffett. This places the large-cap computer services firm just below the 80% threshold that typically indicates strategic interest. The analysis reveals a fundamentally strong company, as ACN passes key criteria for long-term predictable profitability, low debt service, high return on equity, and robust free cash flow generation. However, the overall score is constrained by a notable failure in the 'Initial Rate of Return' criterion, suggesting that despite its operational health, the stock's current valuation does not meet the model's strict requirements for an attractive entry point. The neutral rating on share repurchases is a minor factor, but the valuation test failure is the primary reason the stock does not achieve a higher score within this value-focused framework.

Key Decisions for Investors

• Investors should recognize Accenture as a high-quality company with excellent fundamentals but exercise caution regarding its current valuation, which fails the 'Initial Rate of Return' test in this specific value model.
• For long-term investors following a value discipline, it may be prudent to place ACN on a watchlist, awaiting a more favorable entry point that could improve the potential return profile.
• Investors with a growth-at-any-price mandate might still find the strong fundamental metrics, such as predictable earnings and high returns on capital, compelling, but should acknowledge the stock is trading at a premium that deters strict value strategies.